Stryker (NYSE: SYK) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare Stryker to similar companies based on the strength of its risk, earnings, valuation, analyst recommendations, institutional ownership, dividends and profitability.
Stryker pays an annual dividend of $1.70 per share and has a dividend yield of 1.1%. Stryker pays out 36.3% of its earnings in the form of a dividend. As a group, “Medical Devices & Implants” companies pay a dividend yield of 1.3% and pay out 42.2% of their earnings in the form of a dividend. Stryker has increased its dividend for 6 consecutive years.
Stryker has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Comparatively, Stryker’s peers have a beta of 0.21, meaning that their average stock price is 79% less volatile than the S&P 500.
This is a breakdown of current ratings and price targets for Stryker and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Stryker currently has a consensus price target of $152.37, indicating a potential upside of 0.22%. As a group, “Medical Devices & Implants” companies have a potential upside of 39.99%. Given Stryker’s peers stronger consensus rating and higher possible upside, analysts clearly believe Stryker has less favorable growth aspects than its peers.
Insider and Institutional Ownership
75.0% of Stryker shares are owned by institutional investors. Comparatively, 54.8% of shares of all “Medical Devices & Implants” companies are owned by institutional investors. 7.4% of Stryker shares are owned by insiders. Comparatively, 11.9% of shares of all “Medical Devices & Implants” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Stryker and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Stryker and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Stryker||$11.33 billion||$1.65 billion||32.49|
|Stryker Competitors||$1.67 billion||$207.58 million||65.65|
Stryker has higher revenue and earnings than its peers. Stryker is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Stryker beats its peers on 9 of the 15 factors compared.
Stryker Company Profile
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products. The MedSurg segment includes surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling, emergency medical equipment, intensive care disposable products; reprocessed and remanufactured medical devices, and other related products. The Neurotechnology and Spine segment includes neurovascular products, spinal implant systems and other related products. The Company’s products include implants, which are used in joint replacement and trauma surgeries, and other products that are used in a range of medical specialties.
What are top analysts saying about Stryker Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stryker Corporation and related companies.